Literature DB >> 21976627

Electronic portal imaging vs kilovoltage imaging in fiducial marker image-guided radiotherapy for prostate cancer: an analysis of set-up uncertainties.

S Gill1, J Thomas, C Fox, T Kron, A Thompson, S Chander, S Williams, K H Tai, G Duchesne, F Foroudi.   

Abstract

OBJECTIVES: The purpose of this study was to compare interfraction prostate displacement data between electronic portal imaging (EPI) and kilovoltage imaging (KVI) treatment units and discuss the impact of any difference on margin calculations for prostate cancer image-guided radiotherapy (IGRT).
METHODS: Prostate interfraction displacement data was collected prospectively for the first 4 fractions in 333 patients treated with IGRT with daily pre-treatment EPI or KVI orthogonal imaging. Displacement was recorded in the anteroposterior (AP), left-right (LR) and superoinferior (SI) directions. The proportion of displacement <3 mm and the difference in median absolute displacements were calculated in all directions.
RESULTS: 1088 image pairs were analysed in total, 448 by EPI and 640 by KVI. There were 23% (95% confidence interval [CI] 18-28%) more displacements under 3 mm for EPI than for KVI in the AP direction, 14% (95% CI 10-19%) more in the LR direction and 10% (95% CI 5-15%) more in the SI direction. The differences in absolute median displacement (KVI>EPI) were AP 1 mm, LR 1 mm and SI 0.5 mm. Wilcoxon rank-sum test showed that distributions were significantly different for all three dimensions (p<0.0001 for AP and LR and p=0.02 for SI).
CONCLUSION: EPI has a statistically significant smaller set-up error distribution than KVI. We would expect that, because fiducial marker imaging is less clear for EPI, the clinical target volume to planning target volume margin would be greater when using IGRT; however, relying wholly on displacement data gives the opposite result. We postulate that this is owing to observer bias, which is not accounted for in margin calculation formulas.

Entities:  

Mesh:

Year:  2011        PMID: 21976627      PMCID: PMC3473946          DOI: 10.1259/bjr/13553326

Source DB:  PubMed          Journal:  Br J Radiol        ISSN: 0007-1285            Impact factor:   3.039


  22 in total

1.  A computerized remote table control for fast on-line patient repositioning: implementation and clinical feasibility.

Authors:  A Bel; O Petrascu; I Van de Vondel; L Coppens; N Linthout; D Verellen; G Storme
Journal:  Med Phys       Date:  2000-02       Impact factor: 4.071

2.  The probability of correct target dosage: dose-population histograms for deriving treatment margins in radiotherapy.

Authors:  M van Herk; P Remeijer; C Rasch; J V Lebesque
Journal:  Int J Radiat Oncol Biol Phys       Date:  2000-07-01       Impact factor: 7.038

3.  Portal imaging for evaluation of daily on-line setup errors and off-line organ motion during conformal irradiation of carcinoma of the prostate.

Authors:  H Alasti; M P Petric; C N Catton; P R Warde
Journal:  Int J Radiat Oncol Biol Phys       Date:  2001-03-01       Impact factor: 7.038

Review 4.  Errors and margins in radiotherapy.

Authors:  Marcel van Herk
Journal:  Semin Radiat Oncol       Date:  2004-01       Impact factor: 5.934

5.  Potential and limitations of the automatic detection of fiducial markers using an amorphous silicon flat-panel imager.

Authors:  D Buck; M Alber; F Nüsslin
Journal:  Phys Med Biol       Date:  2003-03-21       Impact factor: 3.609

6.  Extraction of data for margin calculations in prostate radiotherapy from a commercial record and verify system.

Authors:  C Fox; R Fisher; T Kron; K H Tai; A Thompson; R Owen; F Foroudi
Journal:  J Med Imaging Radiat Oncol       Date:  2010-04       Impact factor: 1.735

7.  Target margins for random geometrical treatment uncertainties in conformal radiotherapy.

Authors:  A Bel; M van Herk; J V Lebesque
Journal:  Med Phys       Date:  1996-09       Impact factor: 4.071

8.  Positioning errors and prostate motion during conformal prostate radiotherapy using on-line isocentre set-up verification and implanted prostate markers.

Authors:  J Wu; T Haycocks; H Alasti; G Ottewell; N Middlemiss; M Abdolell; P Warde; A Toi; C Catton
Journal:  Radiother Oncol       Date:  2001-11       Impact factor: 6.280

9.  On-line aSi portal imaging of implanted fiducial markers for the reduction of interfraction error during conformal radiotherapy of prostate carcinoma.

Authors:  Peter W M Chung; Tara Haycocks; Tanya Brown; Zoe Cambridge; Valerie Kelly; Hamideh Alasti; David A Jaffray; Charles N Catton
Journal:  Int J Radiat Oncol Biol Phys       Date:  2004-09-01       Impact factor: 7.038

10.  Comparison of megavoltage position verification for prostate irradiation based on bony anatomy and implanted fiducials.

Authors:  Aart J Nederveen; Homan Dehnad; Uulke A van der Heide; R Jeroen A van Moorselaar; Pieter Hofman; Jan J W Lagendijk
Journal:  Radiother Oncol       Date:  2003-07       Impact factor: 6.280

View more
  4 in total

Review 1.  Fiducial marker guided prostate radiotherapy: a review.

Authors:  Angela G M O'Neill; Suneil Jain; Alan R Hounsell; Joe M O'Sullivan
Journal:  Br J Radiol       Date:  2016-09-23       Impact factor: 3.039

2.  Modern radiotherapy using image guidance for unresectable non-small cell lung cancer can improve outcomes in patients treated with chemoradiation therapy.

Authors:  Matthew P Deek; Sinae Kim; Ning Yue; Rekha Baby; Inaya Ahmed; Wei Zou; John Langenfeld; Joseph Aisner; Salma K Jabbour
Journal:  J Thorac Dis       Date:  2016-09       Impact factor: 2.895

3.  Improved human observer performance in digital reconstructed radiograph verification in head and neck cancer radiotherapy.

Authors:  Jared D Sturgeon; John A Cox; Lauren L Mayo; G Brandon Gunn; Lifei Zhang; Peter A Balter; Lei Dong; Musaddiq Awan; Esengul Kocak-Uzel; Abdallah Sherif Radwan Mohamed; David I Rosenthal; Clifton David Fuller
Journal:  Int J Comput Assist Radiol Surg       Date:  2014-12-05       Impact factor: 2.924

4.  Feasibility of intensity-modulated radiotherapy to treat gastric cancer.

Authors:  Agnieszka Skrobala; Marta Adamczyk; Aldona Karczewska-Dzionk
Journal:  Rep Pract Oncol Radiother       Date:  2018-11-16
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.